Response: NAD targeting efficiently kills hematologic cancer cells
2009
Response
We thank Cea and coauthors for sharing their results on APO866 activity in hematologic malignancies. We reported that primary cells and cell lines from patients with hematologic malignancies are highly sensitive toward APO866.[1][1] Results were obtained from MTT (thiazolyl blue
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
1
References
0
Citations
NaN
KQI